FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and represents a pharmaceutical composition applicable for treating a rheumatic disease and containing the humanised anti-CD4 antibody able to activate CD4+CD25+ regulatory T-cells, and methotrexat. The present invention also discloses a kit and a method of treating the rheumatic disease with using the above pharmaceutical combination and the above kit.
EFFECT: invention enables implementing more effective methods of treating the rheumatic diseases, including rheumatoid arthritis.
57 cl, 8 dwg, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
HUMANISED AHTH-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES | 2004 |
|
RU2375375C2 |
COMPOSITION FOR TREATING ARTHRITIS | 2009 |
|
RU2563360C2 |
METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2012 |
|
RU2670743C9 |
Authors
Dates
2014-10-20—Published
2009-08-31—Filed